Status and phase
Conditions
Treatments
About
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
402 participants in 2 patient groups
Loading...
Central trial contact
Chi Zhang, M.M; Zhaoxiang Wang, M.M
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal